Earnings News - Candlesense

Intapp announces fourth quarter and fiscal year 2025 financial results

PALO ALTO, Calif.--(BUSINESS WIRE)--Intapp, Inc. (NASDAQ: INTA), a leading global provider of AI-powered solutions for professionals at advisory, capital markets, and legal firms, announced financi...

What potential risks or uncertainties were highlighted in the earnings call or press release that could impact the stock's volatility? How might the reported results affect the positioning of Intapp within AI-driven professional services, and could this lead to shifts in market share? What is the projected cash flow generation for FY 2026, and does it support potential dividend initiation or further investment initiatives?

Symbol: INTA

27 days ago

Intellicheck Announces Record Second Quarter 2025 Financial Results

MELVILLE, N.Y.--(BUSINESS WIRE)---- $IDN #InvestorRelations--Intellicheck, Inc. (Nasdaq: IDN), an industry-leading identity company delivering on-demand digital and physical identity validation sol...

What are the potential risks or headwinds highlighted in the earnings call that could impact the stock price? How will the company's capital allocation strategy (e.g., R&D, M&A, share buybacks) influence its long‑term competitive position? Is there any insider buying or selling activity surrounding the earnings announcement that could signal market expectations?

Symbol: IDN

27 days ago

TherapeuticsMD Announces Second Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results ...

What is the expected impact of macro‑economic trends on the company’s royalty revenue? Is there any indication of a potential acquisition or partnership in the pipeline? What is the company's guidance on capital expenditures for the remainder of 2025?

Symbol: TXMD

27 days ago

Fathom Holdings Reports Second Quarter 2025 Results

– Fathom achieved 36% year-over-year revenue growth, driven by 25% transaction growth – CARY, N.C., Aug. 12, 2025 /PRNewswire/ -- Fathom Holdings Inc. (Nasdaq: FTHM) ("Fathom" or the "Company"), a ...

How might the news influence institutional and retail investor sentiment and trading volume for FTHM? What is the expected impact on the company's cash flow, capital expenditures, and balance‑sheet strength? Are there any upcoming regulatory, macro‑economic, or real‑estate market risks that could affect future performance?

Symbol: FTHM

27 days ago

Read more prnewswire

VINCI COMPASS REPORTS SECOND QUARTER 2025 EARNINGS RESULTS

RIO DE JANEIRO, Aug. 12, 2025 /PRNewswire/ -- Vinci Compass Investments Ltd. (NASDAQ: VINP) ("Vinci Compass," "the Company," "we," "us," or "our"), the controlling company of a leading alternative ...

How does the reported sentiment score of 10 align with the qualitative tone of the earnings call and management commentary? Are there any macroeconomic or regional factors highlighted in the report that could influence Vinci Compass's operating environment in the near term? What is the market's reaction to the earnings release in terms of price movement, volume, and analyst revisions?

Symbol: VINP

27 days ago

Read more prnewswire

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end Completed design verification (DV) testing of CELLECTRA® 5PSP device requir...

Could the successful BLA and device verification lead to partnership or licensing opportunities, and what would be the potential impact on valuation? What is the market's current pricing of INOVIO's pipeline assets relative to competitors' similar products? How does INOVIO's current cash runway and financing needs compare to its peers given these upcoming milestones?

Symbol: INO

27 days ago

Read more prnewswire

Caris Life Sciences Reports Second Quarter 2025 Financial Results

IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results for the quarte...

Is there any insider trading activity or significant institutional positioning that could signal market expectations for the stock? What macroeconomic or sector-specific factors could be influencing the company's performance this quarter? How might the reported results influence analyst sentiment and potential upgrades or downgrades of the stock?

Symbol: CAI

27 days ago

Read more prnewswire

QuickLogic Reports Fiscal Second Quarter 2025 Financial Results

SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK) ("QuickLogic" or the "Company"), a developer of embedded FPGA (eFPGA) IP, ruggedized FPGAs, and Endpoint AI sol...

What are the potential risks or headwinds highlighted in the earnings call that could impact the company's outlook? How might the earnings release affect QuickLogic's short‑term stock price momentum and trading volume? Did the company announce any new product launches, partnerships, or contracts that could drive future growth?

Symbol: QUIK

27 days ago

Read more prnewswire

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale o...

How might the sale of the TRELEGY royalty interest affect the company’s valuation multiples (P/E, EV/EBITDA) going forward? What are the tax implications of the TRELEGY royalty sale on the company's net income? What is the outlook for the remaining pipeline assets beyond CYPRESS—any upcoming INDs or trials?

Symbol: TVTK

27 days ago

Read more prnewswire

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES, Aug. 12, 2025 /PRN...

What is the broader market sentiment toward mid‑stage biotech companies with similar cash‑flow profiles, and how might this news shift investor positioning in ARMP? Are there any contingent milestones or covenants tied to the credit agreement that could affect future financing flexibility? How might the Phase 1b/2a results impact the timeline for regulatory submissions and eventual market launch of AP‑SA02?

Symbol: ARMP

27 days ago

Read more prnewswire